Institutional Investor T. Rowe Price Reports 8.9% Stake in BioLife Solutions

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. reports holding 4,246,706 shares of BioLife Solutions common stock, representing 8.9% of the class. The filing is a Schedule 13G filed by an investment adviser (classification IA) and indicates sole voting and sole dispositive power over those shares. The filer certifies the securities were acquired and are held in the ordinary course of business and states they were not acquired to change or influence control of the issuer. The filing also includes a declaration denying beneficial ownership in a closing certification.

Insights

Securities Analyst

Large institutional stake of 8.9% reported; appears passive under Schedule 13G.

The report shows T. Rowe Price holds 4,246,706 shares with sole voting and dispositive power, a sizable position for a single investment manager in this issuer. Because the filing is a Schedule 13G under the investment adviser classification and includes a certification that the position is held in the ordinary course and not to influence control, this appears to be a passive, disclosure-driven holding rather than an activist stake. The position size is material to shareholders who track institutional ownership concentration.

Corporate Governance Expert

Material institutional ownership disclosed, but the filing includes an explicit denial of beneficial ownership.

The filing presents a clear numeric disclosure—4,246,706 shares (8.9%)—while also containing language that the filer "expressly denies" beneficial ownership in its certification. That duality is notable for governance analysts because it raises ambiguity about the economic interest versus reported voting/dispositive authority. The Schedule 13G classification and the certification asserting ordinary-course holdings reduce immediate control concerns, but the denial clause warrants careful reading of any related portfolio or client-account disclosures.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

BIOLIFE SOLUTIONS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

09062W204

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09062W204

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,246,706.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,246,706.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,246,706.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.9 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BIOLIFE SOLUTIONS INC
(b)	Address of issuer's principal executive offices: 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL, WA, 98021
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 09062W204
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4246706
(b)	Percent of class: 8.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4246706
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4246706
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	08/14/2025

FAQ

How many BLFS shares does T. Rowe Price own according to this filing?

4,246,706 shares, representing 8.9% of the class as reported in the Schedule 13G.

Is the T. Rowe Price stake in BLFS active or passive?

The filing is a Schedule 13G under the investment adviser classification (IA) and includes a certification that the securities were acquired and are held in the ordinary course of business and not to influence control, indicating a passive holding.

Does T. Rowe Price have voting power over the BLFS shares reported?

Yes. The filing reports sole voting power and sole dispositive power over the 4,246,706 shares.

Does the filing state any intent to change control of BioLife Solutions (BLFS)?

No. The filer certifies the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing control of the issuer.

Should investors view this as influential institutional ownership?

This is material institutional ownership (8.9%), but the Schedule 13G classification and the certification of passive intent indicate it is reported as a non-activist position.